The likely reason, according to researchers, is that women without insurance are less likely to be screened for cervical cancer. The new study appears online in the American Journal of Public Health.
According to the news release:
The American Cancer Society estimates that 12,170 women will be diagnosed with cervical cancer and 4,220 women will die from the disease in 2012. Although incidence and mortality from cervical cancer have declined dramatically since the introduction of the Pap test, one in three cervical cancer patients is diagnosed only after the cancer has spread to nearby organs and one in ten is diagnosed only after the disease has spread to distant organs (35% and 11% respectively). Prognosis is strongly related to stage: the 5-year relative survival rate is 91.2% for patients with localized disease, but only 57.8% for patients with regional disease and 17.0% for those with distant disease.
Socioeconomic status, race, marital status, and geographic location have all been identified as factors related to late stage at diagnosis among cervical cancer patients. Previous studies also documented age as a significant predictor of advanced stage, although the effects of age and also of insurance status, which are two of the strongest predictors of cervical cancer screening, had not been studied together prior to the current study.
For the current study...researchers led by Stacey Fedewa, MPH reviewed the association between late stage (stage III/IV) cervical cancer and both insurance and age, with adjustment for race/ethnicity and other sociodemographic and clinical factors on 69,739 women diagnosed with invasive cervical cancer between 2000 and 2007 from the National Cancer Database.
More than half (55.5%) of privately insured cervical cancer patients in the observed population were at stage I at diagnosis, compared to 40.2% of Medicaid recipients, and 36.4% of uninsured patients. Meanwhile, 24.03% of privately insured women, 34.51% of those with Medicaid, and 35.22% of those without insurance were diagnosed with advanced disease, described as stages III and IV. Advanced stage also increased with age; the adjusted relative risk among women ≥35 years of age was 1.25 to 2.5 that of women 21-34 years.
"Late stage at diagnosis is likely attributable to underscreening," write the authors. They conclude: "Advanced-stage disease leads not only to poorer quality of life and greater morbidity, but often to higher treatment costs as well. Screening should be made accessible and affordable for all women for whom it is recommended, especially for those at higher risk of advanced-stage disease, such as middle-aged women, Medicaid recipients, and uninsured women."
This program aired on July 20, 2012. The audio for this program is not available.